These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1050 related items for PubMed ID: 28668575

  • 1. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
    van Ravenhorst MB, van der Klis FRM, van Rooijen DM, Knol MJ, Stoof SP, Sanders EAM, Berbers GAM.
    Vaccine; 2017 Aug 24; 35(36):4745-4752. PubMed ID: 28668575
    [Abstract] [Full Text] [Related]

  • 2. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB, van der Klis FRM, van Rooijen DM, Sanders EAM, Berbers GAM.
    Vaccine; 2017 Aug 24; 35(36):4753-4760. PubMed ID: 28647167
    [Abstract] [Full Text] [Related]

  • 3. Immunogenicity, Safety and Antibody Persistence of a Booster Dose of Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine Compared with Monovalent Meningococcal Serogroup C Vaccine Administered Four Years After Primary Vaccination Using the Same Vaccines.
    Vesikari T, Forsten A, Bianco V, Van der Wielen M, Miller JM.
    Pediatr Infect Dis J; 2015 Dec 24; 34(12):e298-307. PubMed ID: 26780033
    [Abstract] [Full Text] [Related]

  • 4. Immunogenicity and Safety of a Quadrivalent Meningococcal ACWY-tetanus Toxoid Conjugate Vaccine 6 Years After MenC Priming as Toddlers.
    Nolan T, Booy R, Marshall HS, Richmond P, Nissen M, Ziegler JB, Baine Y, Traskine M, Jastorff A, Van der Wielen M.
    Pediatr Infect Dis J; 2019 Jun 24; 38(6):643-650. PubMed ID: 31116180
    [Abstract] [Full Text] [Related]

  • 5. Different Dynamics for IgG and IgA Memory B Cells in Adolescents following a Meningococcal Serogroup C Tetanus Toxoid Conjugate Booster Vaccination Nine Years after Priming: A Role for Priming Age?
    Stoof SP, Buisman AM, van Rooijen DM, Boonacker R, van der Klis FR, Sanders EA, Berbers GA.
    PLoS One; 2015 Jun 24; 10(10):e0138665. PubMed ID: 26458006
    [Abstract] [Full Text] [Related]

  • 6. Salivary antibody levels in adolescents in response to a meningococcal serogroup C conjugate booster vaccination nine years after priming: systemically induced local immunity and saliva as potential surveillance tool.
    Stoof SP, van der Klis FR, van Rooijen DM, Bogaert D, Trzciński K, Sanders EA, Berbers GA.
    Vaccine; 2015 Jul 31; 33(32):3933-9. PubMed ID: 26100925
    [Abstract] [Full Text] [Related]

  • 7. Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination.
    van Ravenhorst MB, Marinovic AB, van der Klis FR, van Rooijen DM, van Maurik M, Stoof SP, Sanders EA, Berbers GA.
    Vaccine; 2016 Dec 07; 34(50):6309-6315. PubMed ID: 27817957
    [Abstract] [Full Text] [Related]

  • 8. Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine.
    van Ravenhorst MB, den Hartog G, van der Klis FRM, van Rooijen DM, Sanders EAM, Berbers GAM.
    PLoS One; 2018 Dec 07; 13(4):e0191261. PubMed ID: 29672552
    [Abstract] [Full Text] [Related]

  • 9. Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.
    Borja-Tabora CF, Montalban C, Memish ZA, Boutriau D, Kolhe D, Miller JM, Van der Wielen M.
    BMC Infect Dis; 2015 Oct 06; 15():409. PubMed ID: 26437712
    [Abstract] [Full Text] [Related]

  • 10. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
    Robertson CA, Greenberg DP, Hedrick J, Pichichero M, Decker MD, Saunders M.
    Vaccine; 2016 Oct 17; 34(44):5273-5278. PubMed ID: 27642132
    [Abstract] [Full Text] [Related]

  • 11. Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine.
    de Whalley PC, Snape MD, Kelly DF, Banner C, Lewis S, Diggle L, John TM, Yu LM, Omar O, Borkowski A, Pollard AJ.
    Pediatr Infect Dis J; 2011 Nov 17; 30(11):e203-8. PubMed ID: 21673612
    [Abstract] [Full Text] [Related]

  • 12. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
    Klein NP, Habanec T, Kosina P, Shah NR, Kolhe D, Miller JM, Hezareh M, Van der Wielen M.
    Vaccine; 2018 Apr 19; 36(17):2356-2363. PubMed ID: 29576307
    [Abstract] [Full Text] [Related]

  • 13. Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naïve toddlers: A randomised, controlled trial.
    Knuf M, Rämet M, Breinholt Stærke N, Bertrand-Gerentes I, Thollot Y, B'Chir S, Arroum H, Oster P.
    Hum Vaccin Immunother; 2022 Nov 30; 18(5):2052657. PubMed ID: 35445641
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Randomized Trial to Compare the Immunogenicity and Safety of a CRM or TT Conjugated Quadrivalent Meningococcal Vaccine in Teenagers who Received a CRM or TT Conjugated Serogroup C Vaccine at Preschool Age.
    Ishola DA, Andrews N, Waight P, Yung CF, Southern J, Bai X, Findlow H, Matheson M, England A, Hallis B, Findlow J, Borrow R, Miller E.
    Pediatr Infect Dis J; 2015 Aug 30; 34(8):865-74. PubMed ID: 26075813
    [Abstract] [Full Text] [Related]

  • 16. Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine.
    Vesikari T, Forsten A, Bianco V, Van der Wielen M, Miller JM.
    Hum Vaccin Immunother; 2016 Aug 30; 12(1):132-9. PubMed ID: 26575983
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.
    Dbaibo G, El-Ayoubi N, Ghanem S, Hajar F, Bianco V, Miller JM, Mesaros N.
    Drugs Aging; 2013 May 30; 30(5):309-19. PubMed ID: 23494214
    [Abstract] [Full Text] [Related]

  • 20. Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents.
    Quiambao BP, Jain H, Bavdekar A, Dubey AP, Kolhe D, Bianco V, Van der Wielen M, Miller JM.
    Hum Vaccin Immunother; 2016 Aug 02; 12(8):2162-2168. PubMed ID: 27152501
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.